InvestorsHub Logo
Followers 15
Posts 1318
Boards Moderated 0
Alias Born 07/27/2015

Re: sage4 post# 126389

Thursday, 10/26/2017 5:25:53 AM

Thursday, October 26, 2017 5:25:53 AM

Post# of 462856
Veronica Francardo, the Dr. and author of the therapeutics poster, used that very same title some years ago.

“Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism”

Interesting read to see how she thought of sigma-1 back in 2014.


In the last years several studies also reported anti-amnesic and neuroprotective effects of Sig-1R ligands in animal models of AD (Maurice and Su, 2009). Clinical trials in patients with AD are now ongoing (further informations can be found at www.anavex.com), and the aim for the future is to accelerate the steps from preclinical to clinical trials also on PD patients.


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281425/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News